DESTIN, Fla. — Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East.
In her presentation, Avery H. LaChance, MD, MPH, director of the Connective Tissue Diseases Clinic at Brigham and Women’s Hospital, and assistant professor of dermatology at Harvard Medical School, said she has moved on from hydroxychloroquine as a first-line systemic therapy for systemic dermatomyositis.
“The only time I am reaching for hydroxychloroquine is in patients with super mild disease,”